Skip to main content
. 2023 Jan 8;12(2):520. doi: 10.3390/jcm12020520

Table 2.

Baseline and transplant characteristics of patients enrolled.

Age (Years) Mean (Range) 52.5 (23–68)
Sex, males/females N (%) 7 (41.2)/10 (58.8)
Hematological disease
  • -

    AML

  • -

    HL

  • -

    MDS

  • -

    PMF

  • -

    ALL

 N (%)  
8 (47.1)
2 (11.7)
3 (17.7)
3 (17.7)
1 (5.8)
Refined DRI
  • -

    Low

  • -

    Intermediate

  • -

    High

 N (%)  
10 (58.8)
4 (23.5)
3 (17.7)
Status disease
  • -

    Complete response/remission

  • -

    Partial response/remission

  • -

    Active disease

 N (%)  
12 (70.6)
2 (11.7)
3 (17.7)
Transplant type
  • -

    Related

  • -

    Unrelated

 N (%)  
9 (52.9)
8 (47.1)
Cells source
  • -

    PBSC

  • -

    Bone marrow

 N (%)  
14 (82.3)
3 (17.7)
HLA match
  • -

    7/8

  • -

    Full matched

  • -

    Haploidentical

 N (%)  
1 (5.8)
13 (76.5)
3 (17.7)
Conditioning regimen
  • -

    Myeloablative

  • -

    Non myeloablative

 N (%)  
17 (100)
0 (0)
HCT-CI
  • -

    0

  • -

    1

 N (%)  
14 (82.3)
3 (17.7)
ATG use, yes/no N (%) 6 (35.3) /11 (64.7)
Karnofsky Performance Score
  • -

    ≥90

  • -

    <90

 N (%)  
17 (100)
0 (0)
Basal Bilirubin (mg/dL) Mean (range) 0.56 (0.3–1.15)
Basal Creatinine (mg/dL) Mean (range) 0.72 (0.32–1.18)

AML: acute myeloid leukemia; HL: Hodgkin lymphoma; MDS: myelodysplastic syndrome; PMF: primary myelofibrosis; ALL: acute lymphoblastic leukemia; DRI: disease risk index; PBSC: peripheral blood stem cells; HLA: human leukocyte antigen; HCT-CI: HCT-Comorbidity Index; ATG: anti-thymocyte globulins.